Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 26;24(1):431.
doi: 10.1186/s12876-024-03503-5.

Clinical application of capsule sponge testing in symptomatic reflux disease: a national prospective cohort study

Siobhan Chien  1   2 , Paul Glen  3 , Gavin Bryce  4 , Neil Cruickshank  5 , Ian Penman  6 , Kevin Robertson  7 , Perminder Phull  8 , Andrew Crumley  9 , Ivan Gunjaca  10 , Jeyakumar Apollos  11 , Michael Miller  12 , Jonathan Fletcher  13 , Grant Fullarton  14
Affiliations

Clinical application of capsule sponge testing in symptomatic reflux disease: a national prospective cohort study

Siobhan Chien et al. BMC Gastroenterol. .

Abstract

Background: Capsule sponge testing, using an oesophageal cell collection device with biomarkers, was implemented nationally across Scotland in 2020 for symptomatic reflux patients referred to secondary care for non-urgent endoscopy. The aim was to use capsule sponge testing as a triage tool to reduce pressures on the endoscopy service during COVID-19, focus endoscopy resources on those most likely to have pathology and streamline the patient pathway. This prospective cohort study presents the first real-world results and evaluates the clinical application of capsule sponge testing in symptomatic reflux disease based on endoscopic biopsy results.

Methods: Over a 32-month period, all patients undergoing capsule sponge testing for investigation of reflux symptoms across 11 Scottish health boards were identified from prospectively maintained databases. Individual patient records were interrogated to collect baseline demographics, capsule sponge test result (TFF3/atypia/p53) and ongoing clinical management. Further analysis was performed on patients who subsequently underwent upper gastrointestinal (UGI) endoscopy.

Results: 1385 tests were performed for reflux symptoms in 1305 patients. The median follow-up time was 20 months (IQR 12-27). 1103/1385 tests (79.6%) were negative for biomarkers. 913/1305 (70.0%) patients were discharged with no additional investigation required. 355/1305 patients (27.2%) underwent UGI endoscopy due to a positive or insufficient result or ongoing symptoms. With insufficient tests excluded, 52/314 patients (16.6%) had intestinal metaplasia (IM) on endoscopic biopsies, which strongly correlated with positive biomarkers (88.5% vs. 11.5%; p < 0.001), including 1 case of dysplasia. 10/1103 sponge negative patients (0.9%) had biopsies demonstrating IM (n = 6) or malignancy (n = 4): 1 patient was diagnosed with oesophageal adenocarcinoma 27 months later and 3 patients had gastric malignancy, which relies on symptom assessment to direct to endoscopy since the capsule sponge is an oesophageal test.

Conclusions: Capsule sponge testing is effectively at identifying the 30% of symptomatic reflux patients requiring further investigation with UGI endoscopy and aiding the diagnosis of Barrett's oesophagus in clinical practice. Judicious follow-up of the discharged group will be critical to validate the ongoing use of capsule sponge testing long-term.

Keywords: Barrett’s oesophagus; Capsule sponge testing; Gastro-oesophageal reflux disease; Reflux.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Ethical approval was obtained via local information governance teams in each health board, in addition to Public Benefit and Privacy (PBPP) approval on a national level from the Caldicott guardian (NHS Scotland Public Benefit and Privacy Panel for Health and Social Care; NHS Scotland). This was approved with the need for individual patient consent waived due to the retrospective nature of data collection and for the purposes of service development as per NHS Scotland PBPP for Health and Social Care. All patients signed a National Health Service (NHS) consent form prior to the procedure. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Patient workflow and clinical management based on capsule sponge test result within the symptomatic reflux group (n = 1385)
Fig. 2
Fig. 2
Summary of workflow of all valid capsule sponge results (n = 1243). 142 insufficient tests are excluded
See this image and copyright information in PMC

References

    1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–80. - PMC - PubMed
    1. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31. - PubMed
    1. Saha B, Vantanasiri K, Mohan BP, Goyal R, Garg N, Gerberi D et al. Prevalence of Barrett’s Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023. - PMC - PubMed
    1. Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: risk factors, screening and endoscopic treatment in western and eastern countries. World J Gastroenterol. 2015;21(26):7933–43. - PMC - PubMed
    1. El-Serag HB, Naik AD, Duan Z, Shakhatreh M, Helm A, Pathak A, et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut. 2016;65(8):1252–60. - PubMed